Risk of suicidal self-directed violence among US veteran survivors of head and neck cancer - Nugent SM, Morasco BJ, Handley R, Clayburgh D, Hooker ER, Ganzini L, Knight SJ, Chen JI, Sullivan DR, Slatore CG.
IMPORTANCE: Head and neck cancer (HNC) survivors are about twice as likely to die by suicide compared with other cancer survivors. OBJECTIVE: To examine the associations between precancer mental health and pain and postcancer receipt of mental heal... (Source: SafetyLit)
Source: SafetyLit - October 11, 2021 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news

Nanobiotix highlights ASTRO research studies
Nanobiotix will present results from clinical trials of its NBTXR3 radioenhance...Read more on AuntMinnie.comRelated Reading: ASTRO to require masks at October annual meeting PET/CT shows promise predicting outcomes in head, neck cancer ASTRO commits to October in-person annual meeting in Chicago RT + immunotherapy = head/neck cancer treatment option Nanobiotix plans head and neck cancer treatment trial (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 7, 2021 Category: Radiology Source Type: news

Nivolumab more effective, but too costly, for head and neck cancer in Brazil
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2021 Category: Drugs & Pharmacology Source Type: news

The multidimensional prognostic index as a measure of frailty in elderly patients with head and neck cancer - Bakas AT, Sewnaik A, van Straaten J, Baatenburg de Jong RJ, Mattace-Raso FUS, Polinder-Bos HA.
PURPOSE: The multidimensional prognostic index (MPI) is a prognostic model derived from the comprehensive geriatric assessment (CGA) which can predict 1-year mortality risk in elderly individuals. We hypothesized that the MPI also reflects the degree of fr... (Source: SafetyLit)
Source: SafetyLit - September 27, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

What 9/11 Survivors and First Responders Have Taught Us About Public Health in the 20 Years Since the Attacks
Dr. David Prezant was knocked fully airborne at 9:59 on the morning of Sept. 11, 2001. He didn’t see the impact coming, but he felt it when it hit—and it nearly killed him. Little more than an hour earlier, Prezant, then the deputy chief medical officer of the Fire Department of New York, was headed for his usual workplace at the FDNY’s Office of Medical Affairs, just across the Manhattan Bridge in Brooklyn. He had already heard that a plane had hit the North Tower of the World Trade Center, and he reckoned that it was an accident. By the time he reached his office, however, the South Tower had been struc...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger and Tara Law Tags: Uncategorized healthscienceclimate Source Type: news

Human Papillomavirus-Associated Head and Neck Cancer Human Papillomavirus-Associated Head and Neck Cancer
Review the epidemiology, screening, presentation, diagnosis, prognosis, and prevention of HPV-positive oropharyngeal squamous cell carcinoma, with a focus on the primary care provider's role.Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

NIDCR's Fall 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   NIDCR News 5 Q&As About “Oral Health in America: Advances and Challenges” NIDCR issued a brief Q&A regarding details of the forthcoming report Oral Health in America: Advances and Challenges, which will be published in Fall 2021. This comprehensive report will examine improvements in oral health over t...
Source: NIDCR Science News - September 1, 2021 Category: Dentistry Source Type: news

Suicide Risk Found to be Significantly High in Head And Neck Cancer, Especially in Rural Populations
Summarizes the findings of a study on death by suicide in head and neck cancer patients, noting 50% higher rates of suicide for rural patients. Reports that the majority of the 405 reported deaths by suicide were among non-Hispanic males and that the median time between diagnosis and suicide was 26 months. Discusses the implications of these findings on suicide prevention and rural health nationwide. (Source: News stories via the Rural Assistance Center)
Source: News stories via the Rural Assistance Center - August 7, 2021 Category: Rural Health Source Type: news

Re: More evidences are needed in reducing the suicide risk in head and neck cancer patients - Twigg JA, Anderson JM, Humphris G, Nixon I, Rogers SN, Kanatas A.
We thank the authors for their interest in our review paper 'Best practice in reducing the suicide risk in head and neck cancer patients: a structured review' and for their constructive and insightful comments. While there are multiple observational studie... (Source: SafetyLit)
Source: SafetyLit - July 28, 2021 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Incidence and risk of suicide among patients with head and neck cancer in rural, urban, and metropolitan areas - Osazuwa-Peters N, Barnes JM, Okafor SI, Taylor DB, Hussaini AS, Adjei Boakye E, Simpson MC, Graboyes EM, Lee WT.
IMPORTANCE: Patients with head and neck cancer (HNC) are known to be at increased risk of suicide compared with the general population, but there has been insufficient research on whether this risk differs based on patients' rural, urban, or metropolitan r... (Source: SafetyLit)
Source: SafetyLit - July 27, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Head, neck cancer patients at up to 5-fold higher risk for suicide compared to general population, study finds
People with head and neck cancers have an up to five times higher risk for suicide compared to the general population, an analysis published Friday by JAMA Otolaryngology-Head and Neck Surgery found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 23, 2021 Category: Consumer Health News Source Type: news

Heart Failure Tied to Increased Cancer Risk, Study Finds
People with heart failure may live for many years and should continue to get regular cancer screenings, experts say. (Source: NYT Health)
Source: NYT Health - July 19, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Smoking and Tobacco Head and Neck Cancer Heart Alcoholic Beverages Diabetes Source Type: news

NIDCR Science News - July 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. Mimicking Mother Nature to Grow a Gland New video shows how scientists achieved first key step in growing an artificial salivary gland NIDCR • July 2, 2021 A Four-Decade Quest to Uncover a Molecular Secret Scientist's lifelong research could hold clues to brain disorders, cancer NIDCR • June 21, 2...
Source: NIDCR Science News - July 6, 2021 Category: Dentistry Source Type: news

NIDCR's Summer 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR to Release Report on Oral Health in America As a 20-year follow-up to the seminal Oral Health in America: A Report of the Surgeon General, NIDCR will release Oral Health in America: Advances and Challenges in the fall of 2021. The report will illuminate new directions...
Source: NIDCR Science News - July 1, 2021 Category: Dentistry Source Type: news

CU Cancer Center receives highly competitive SPORE grant for head and neck cancer
(University of Colorado Anschutz Medical Campus) Research and treatment of head and neck cancers at the University of Colorado Cancer Center reached a new level this month with a highly competitive Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI). The SPORE was approved by NCI Scientific Program leadership for FY2021 funding; the projected starting date is July 1. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 21, 2021 Category: International Medicine & Public Health Source Type: news

NIH supports mathematical optimization of tumor treatment
(Rice University) A Rice University engineer's mathematical model to reduce the side effects suffered by patients undergoing treatment for head and neck cancers now has the support of the National Institutes of Health. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: E6-specific inhibitors as therapeutics for HPV+ head and neck carcinomas
(Impact Journals LLC) " Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence. " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Head and neck cancer cells hijack nearby healthy tissue, promoting further invasion of cancer cells
(University of Michigan) Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors--tumors that often spread and are difficult to treat. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2021 Category: Cancer & Oncology Source Type: news

Study shows how fungi and bacteria can activate genes associated with head and neck cancer
(Funda ç ã o de Amparo à Pesquisa do Estado de S ã o Paulo) A research group at S ã o Paulo State University (UNESP) analyzed how Candida albicans fungi and Staphylococcus aureus bacteria influence gene expression and tumor cell survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 25, 2021 Category: Cancer & Oncology Source Type: news

Epigenetic Age Acceleration Up in Head and Neck Cancer
Correlation found for increased EAA with elevated fatigue, which was mediated by inflammatory markers CRP, IL - 6 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 24, 2021 Category: Cancer & Oncology Tags: Oncology, ENT, Pathology, Radiology, Journal, Source Type: news

Epigenetic Age Acceleration Up in Head and Neck Cancer
MONDAY, May 24, 2021 -- Patients with head and neck cancer have increased epigenetic age acceleration (EAA), which is associated with fatigue and inflammation, according to a study published online May 24 in Cancer. Canhua Xiao, R.N., Ph.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 24, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: The appearance of skin cancer to look out for – basal cell carcinoma
CANCER may develop on skin exposed to the sun, especially on the face, head and neck. Slow-growing basal cell carcinoma can have a distinctive appearance. Find out what to look out for at Express.co.uk. (Source: Daily Express - Health)
Source: Daily Express - Health - May 22, 2021 Category: Consumer Health News Source Type: news

More evidence is needed to reduce the risk of suicide in head and neck cancer patients - Du L, Chen HL.
We read with interest a structured review by Twigg et al, which evaluated the prevalence of suicide in head and neck cancer (HNC) survivors and appropriate interventions to reduce the risk of suicide in head and neck cancer patients, and commend the author... (Source: SafetyLit)
Source: SafetyLit - May 13, 2021 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

UCLA team discovers how to restrict growth, spread of head and neck cancers
(University of California - Los Angeles) Researchers from the UCLA School of Dentistry have discovered a key molecule that allows cancer stem cells to bypass the body's natural immune defenses, spurring the growth and spread of head and neck squamous cell cancers. Their study, conducted in mice, also demonstrates that inhibiting this molecule derails cancer progression and helps eliminate these stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

UCLA team discovers how to restrict growth, spread of head and neck cancers
Researchers from the  UCLA School of Dentistry have discovered a key molecule that allows cancer stem cells to bypass the body’s natural immune defenses, spurring the growth and spread of head and neck squamous cell cancers. Their study, conducted in mice, also demonstrates that inhibiting this molecule derails cancer progression and helps e liminate these stem cells.  Published today in the journal Cell Stem Cell, the findings could help pave the way for more effective targeted treatments for this highly invasive type of cancer, which is characterized by frequent resistance to therapies, rapid metasta...
Source: UCLA Newsroom: Health Sciences - May 3, 2021 Category: Universities & Medical Training Source Type: news

Inflammation and inflammatory markers of head and neck tumor
(Bentham Science Publishers) This research book aims to highlight the significant roles of inflammation in head and neck malignancy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2021 Category: Cancer & Oncology Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

Genetic changes in head and neck cancer, immunotherapy resistance identified
(University of California - San Diego) A multi-institutional team of researchers, led by UC San Diego School of Medicine and Moores Cancer Center, has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least likely to respond to immunotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2021 Category: International Medicine & Public Health Source Type: news

A new method for fighting 'cold' tumors
(University of Colorado Anschutz Medical Campus) Researchers Michael Knitz and radiation oncologist and University of Colorado Cancer Center member Sana Karam, MD, PhD, address cold tumors in new research published this week in the Journal for ImmunoTherapy of Cancer. Working with mouse models in Karam's specialty area of head and neck cancers, Knitz and Karam studied the role of T cells in tumor treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2021 Category: International Medicine & Public Health Source Type: news

Mayo Clinic Q & amp;A podcast: Head and neck cancers are becoming increasingly common
There are many causes of head and neck cancers, and treatment is complicated. And one of the fastest growing demographic of cancers in the U.S. is human papillomavirus (HPV) in younger people, says Dr. Daniel Ma, a Mayo Clinic radiation oncologist. "This is a treatable disease," says Dr. Ma. "It's a disease that's very responsive [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 19, 2021 Category: Databases & Libraries Source Type: news

Infographic: Transoral head & amp; neck surgery
Learn more about head and neck cancers. More health tip inforgraphics:?mayohealthhighlights.startribune.com (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 14, 2021 Category: Databases & Libraries Source Type: news

Negative Results When Immunotherapy Was Added Onto Radiation Negative Results When Immunotherapy Was Added Onto Radiation
A phase 3 trial investigating the addition of immunotherapy to avelumab onto chemoradiotherapy in patients with head and neck cancer was stopped early.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

NIDCR Science News - April 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. SARS-CoV-2 May Infect the Mouth NIDCR-led study points to role for saliva in spread of virus NIDCR • March 25, 2021 A Safe Space in the Dental Clinic Making dental visits more soothing for children with autism NIDCR • March 23, 2021 How Fungus Finds A Foothold in the Mouth Overactive ...
Source: NIDCR Science News - April 5, 2021 Category: Dentistry Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
(University of California - Los Angeles) By targeting an enzyme that plays a key role in head and neck cancer cells, UCLA researchers were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2021 Category: Cancer & Oncology Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Cancer symptoms: The first warning sign of nasopharyngeal cancer - a painless swelling
CANCER at the back of the nose, down to the throat - a type of head and neck disease - is called nasopharyngeal cancer. What are the symptoms of this deadly condition? And what are the risk factors? (Source: Daily Express - Health)
Source: Daily Express - Health - March 22, 2021 Category: Consumer Health News Source Type: news

Financial Toxicity and Survival of Patients With Cancer Financial Toxicity and Survival of Patients With Cancer
Patients with head and neck cancer who reported a high level of financial difficulty were found to have a shorter survival than patients who did not.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 17, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news

Lithium chloride promotes recovery of radiation-induced oral mucositis and dysgeusia
(International& American Associations for Dental Research) Oral mucositis and taste dysfunction (dysgeusia) occurs in nearly all patients receiving head and neck radiotherapy and tremendously affects the quality of life and treatment outcome. The study " LiCl Promotes Recovery of Radiation-Induced Oral Mucositis and Dysgeusia " published in the Journal of Dental Research (JDR), investigated the hypothesis that lithium chloride (LiCl) can promote the restoration of oral mucosa integrity and taste function after radiation. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 11, 2021 Category: Cancer & Oncology Source Type: news

'Dirty' cancer biotech startup cleans up in $525M build-to-buy deal with big pharma
Maverick's drugs — two of which enter clinical trials this year — are aimed at precisely attacking tumors in head and neck, lung, breast, prostate and other cancers while leaving nearby healthy tissue untouched. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 9, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

Oral and maxillofacial reconstruction featured in Journal of the California Dental Association
 Contact: Alicia Malaby916.554.5372alicia.malaby@cda.orgSacramento, Calif. – The March 2021 issue of the Journal of the California Dental Association features the latest advances in oral and maxillofacial reconstruction. Articles discuss dental implants, modern temporomandibular joint surgery, contemporary sleep surgery and the diagnosis and treatment of oral cavity and oropharyngeal cancer.“This issue, followed by an upcoming issue on head and neck cancers, will augment health care providers’ understanding of several technical and complex areas of dentistry,” ...
Source: Dental Technology Blog - March 4, 2021 Category: Dentistry Source Type: news

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news

Division of Oncology 2 (DO2)
The Division of Oncology 2 (DO2) regulates Investigational New Drug Applications (INDs), New Drug Applications (NDAs) and Biologic Licensing Applications (BLAs) for the following therapeutic areas: gastrointestinal, lung, and head and neck cancers; neuro-oncology, rare cancers, pediatric (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 28, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

University of Cincinnati research unveils possible new combo therapy for head and neck cancer
(University of Cincinnati) Researchers at the University of Cincinnati have tested a new combination therapy in animal models to see if they could find a way to make an already effective treatment even better. Since they're using a Food and Drug Administration-approved drug to do it, this could help people sooner than later. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2021 Category: International Medicine & Public Health Source Type: news